L

Leap Therapeutics
D

LPTX

2.52000
USD
-0.01
(-0.40%)
Market Closed
Volume
9,522
EPS
-2
Div Yield
-
P/E
-2
Market Cap
96,561,100
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CLDX
    -2.200
    (-8.55%)
    23.530 USD
    L
    LPCN
    -0.32000
    (-6.14%)
    4.89000 USD
    O
    ONTX
    0
    (0%)
    0.000000 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    More
News

Title: Leap Therapeutics

Sector: Healthcare
Industry: Biotechnology
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .